Myeloma

As we near the end of 2024, CURE is looking back at the top FDA approval stories of the year.

Patients newly diagnosed with multiple myeloma who are transplant ineligible or deferred may benefit from receiving a Darzalex treatment combination.

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

Black patients may be more affected by certain side effects from Talvey compared with White patients with multiple myeloma, an expert told CURE®.

Updated data from the phase 3 DREAMM-7 trial was presented during the 2024 ASH Annual Meeting and Exposition.

Tecvayli alone or plus Revlimid has been found to be safe and may result in high MRD-negativity rates.

The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with smoldering multiple myeloma.

For patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma, the addition of Darzalex to VRd improved MRD responses as well as progression-free survival.

The FDA has accepted a biologics license application for Blenrep plus bortezomib or pomalidomide for patients with relapsed or refractory multiple myeloma.

Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be presented at an upcoming conference.

Patients with relapsed or refractory multiple myeloma should consider quality of life with survival when choosing the most suitable treatment option.

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

In patients with relapsed or refractory multiple myeloma, KRd56 and KRd27 showed similar effectiveness and safety, but other treatment options may be better.

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

From “The Office” star opening up in a new interview to Charley Steiner revealing his multiple myeloma journey, here is this week’s cancer news.

From “Boy Meets World” actress Danielle Fishel discussing her breast cancer surgery to a young TikTok star dying from a rare liver cancer, here’s what’s happening in the cancer space this week.

Ninlaro, Thalomid and dexamethasone followed by Ninlarlo maintenance may improve durability of response in myeloma after stem cell transplantation relapse.

The biologics license application seeks potential approval of a Darzalex Faspro-based regimen for newly diagnosed multiple myeloma ineligible for transplant.

Reflecting on the pain I experienced before my diagnosis of multiple myeloma, I realized how important it was to pay attention to the related symptoms.

CAR-T cell therapies administered in an outpatient setting may be safe and feasible without intensive remote monitoring in hematologic malignancies.

The Food and Drug Administration has approved Sarclisa as a first-line treatment for patients with multiple myeloma who are ineligible for autologous stem cell transplant.

From model Bianca Balti’s ovarian cancer diagnosis to hockey pro’s testicular cancer diagnosis, here’s what’s happening in the oncology space this week.

From Princess Kate entering ‘a new phase of recovery’ to a Rock and Roll Hall of Famer’s blood cancer announcement, here’s what’s happening in the cancer space this week.

A Darzalex-based regimen improved MRD negativity rates compared with VRd in patients with newly diagnosed, transplant-eligible multiple myeloma.

Since my diagnosis with multiple myeloma, I try to keep inspired to keep moving forward despite the challenges.

Boruzu, an injectable presentation of Velcade, has been approved by the FDA for patients who either have multiple myeloma or mantle cell lymphoma.

Three years after the first FDA approval of CAR-T cell therapy, patients with multiple myeloma are starting to see the therapy emerge in earlier lines.

CAR-T cell therapy is moving to earlier lines of multiple myeloma treatment.

As soon as I entered complete remission for multiple myeloma, I felt a glimmer of hope.

Patients with multiple myeloma now have several available treatment options, so it’s important to have answers to some of the frequently asked questions.